Therapeutic potential of mTOR inhibitors for targeting cancer stem cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant activation of the mammalian target of rapamycin (mTOR) pathway is common in various cancers.
• First-generation mTOR inhibitors faced challenges in clinical efficacy due to feedback mechanisms in oncogenetic circuits.
• Cancer stem cells (CSCs) are crucial for tumor recurrence and resistance, necessitating targeted therapies that eliminate them.

Purpose of the Study:

• To evaluate the potential of the mTOR pathway as a therapeutic target in cancer.
• To explore the efficacy of newly developed mTOR inhibitors against cancer stem cells.
• To assess the differential effects of mTOR inhibitors on normal versus malignant stem cells.

Main Methods:

• Review of current research on mTOR pathway regulation in cancer.
• Analysis of clinical trial data for first and next-generation mTOR inhibitors.
• Examination of studies investigating the impact of mTOR inhibitors on cancer stem cell populations.

Main Results:

• Newly developed mTOR inhibitors demonstrate greater promise compared to earlier generations.
• Some mTOR inhibitors exhibit a preferential inhibitory effect on cancer stem cells.
• The mTOR pathway plays an opposing role in normal and malignant stem cells, making it a viable target.

Conclusions:

• The mTOR pathway is a compelling therapeutic target for cancer treatment.
• Next-generation mTOR inhibitors offer a promising strategy for selectively eliminating cancer stem cells.
• Targeted mTOR inhibition warrants further clinical development for anti-cancer therapies.